Company intelligence / Profile preview

Oak Hill Bio

Altrincham, Cheshire, United Kingdom

Ownership: Private
Development stage: Phase 2

Overview

Rugonersen showed promising clinical data for Angelman syndrome. OHB-607 showed statistically significant shift towards milder bronchopulmonary dysplasia and positive trend in reducing intraventricular hemorrhage in Phase 2 trial.

Therapeutic areas: OphthalmologyPulmonologyNeurology
Modalities: Antisense oligonucleotide (ASO)Recombinant protein (IGF-1/IGFBP-3)Plasma kallikrein inhibitor
Industry: Biotech

Drug pipeline

8 assets

rugonersen

7 more assets in the full pipeline.

Request access →

Partnerships

Roche (licensed rugonersen)Chiesi Group (license and development agreement for OHB-607)Takeda (acquired pipeline from)

Beyond the preview

Go deeper on Oak Hill Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oak Hill Bio.

Explore the full profile